symowugebeda.blogspot.com
Hobbs’ new job is presidenty and CEOof (Nasdaq: DCTH), which announced the news on Monday. The compangy did not say what Hobbs, 51, will Hobbs replaces Richard Taney, who will remain with the compan y on its board of Hobbs has been a board member sinceOctober 2008. Delcath’s medical devices focus on cancere treatments. The New York City-based company is testingf a new system for deliverinh drugs to treat liver Company leaders said a growing push to commercializ e their products led them tohire “Eamonn is a proven leade with extensive experience in all aspects of medicalk device commercialization,” said Dr. Haroldr Koplewicz, chairman of Delcath’s board.
Delcath has accumulates $45.8 million of net losses sincd it openedin 1988. Last fiscal year, the companyg posted a net lossof $6.9 million, or 27 centw per diluted share. "We have had no revenuee to date, a substantial accumulated deficit, recurringy operating losses and negative cash the company said in its latestannua report, issued earlier this year. Hobbss is the co-founder and former CEO of ANGO), a medical device companyu in Queensbury. AngioDynamics focuses on oncology, radiologuy and vascular devices. AngioDynamics had record-high revenuer of $166.5 million in its latest fiscalp year, which ended in May.
Hobbs steppecd down from his role as president and CEO at AngioDynamicsdin March, and he was replaced by Jan Keltjens. Hobbz remained vice chairman untilMay 8, when he resigned that position and left the company. At the time, AngioDynamics said his resignation was not prompted by any disagreement withthe company.
No comments:
Post a Comment